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secretion and systemic macrophage activation. Since per-
oxisome proliferators activated receptor (PPAR) agonists,
regulators of cholesterol metabolism, have been shown to
exhibit profound effects on the inhibition of proinﬂamma-
tory cytokines and macrophage activation, rosiglitazone, a
PPAR-gamma agonist, was adopted for the potential con-
trol of HPS using a rabbit model of Herpesvirus papio
(HVP, an EBV homologue)-associated HPS. In vitro, rosigli-
tazone was shown to inhibit macrophage activation and
secretion of tumor necrosis factor-alpha through inhibi-
tion of NFkB signaling in U937 cell line. Different doses of
rosiglitazone were fed to rabbits after intravenous injec-
tion of 5× 107 copies of HVP virus at different time courses
(7 days and 20 days, respectively) of infection. As com-
pared to the control group which succumbed consistently
at around one month, the 4mg rosiglitazone-treated group
showed signiﬁcant improvement of survival when fed at
early stage (7 days) of infection (p < 0.01), while a higher
dosage (8mg) is needed to achieve therapeutic effect at
advanced stage (20 days) of infection (p < 0.05). The viral
load, TNF-alpha cytokine levels, and laboratory parameters
also showed signiﬁcant improvement in the rosiglitazone-
treated group. Therefore, rosiglitazone, in addition to its
therapeutic effect for metabolic syndrome, appears to rep-
resent a potential regimen for the control of HPS associated
with virus infections.
doi:10.1016/j.ijid.2008.05.420
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Background: Dengue virus (DENV), a member of the Fla-
viviridae family is the leading cause of diseases ranging
from febrile Dengue Fever to life-threatening Dengue Hem-
orrhagic Fever/Dengue Shock Syndrome. Each year, millions
are infected with the virus; however, the race to ﬁnd a
suitable therapy or prophylaxis for DENV is complicated
by the existence of 4 serotypes of DENV and the advent
of antibody-mediated enhancement (ADE). In the light of
this re-emerging disease, our group has taken the proac-
tive approach to study the entry pathway of Dengue virus
serotype 2 (DENV2) into HepG2 hepatocytes. Armed with this
new-found knowledge, we hope to be able to contribute fur-
ther to the understanding and the development of effective
anti-dengue strategies.
Methods: Our experiment was divided into three main
areas; (1) using drug inhibitory assays against candidate
host factors mediating virus endocytosis, (2) using molec-
ular inhibitors and siRNA molecules against these host
factors as a molecular approach to supplement our results
and (3) employing the use of indirect immunoﬂuorescence
microscopy for bio-imaging studies tracking DENV2 entry
into HepG2 within the ﬁrst 30 minutes of infection.
Results: Our virus growth curve shows productive DENV2
infection of HepG2 cells from the point of infection to 10
days post-infection. We embarked on using small molecule
drugs against host factors identiﬁed as having a crucial role
in mediating DENV2 entry into HepG2 cells. These include
clathrin, acidiﬁcation of endosomes, host cytoskeleton net-
work (actin and microtubule) as well as lipid rafts. All drug
inhibition assays carried out show a non-cytotoxic dose-
dependent inhibition of DENV2 entry into cells. Likewise,
we used molecular inhibitors and siRNA molecules against
these cellular factors showed similar results. Finally, our bio-
imaging studies further reveal a stepwise entry of DENV2
into HepG2 cells starting with clathrin-mediated endocy-
tosis followed by co-localization with early and then late
endosomes.
Conclusion: Our study gives us a ﬁrst glimpse of the intri-
cate interaction of host factors that mediate DENV2 entry
into HepG2 cells and provides us with an avenue to develop
therapeutic approached to target this crucial initial interac-
tion to combat DENV infection in general.
doi:10.1016/j.ijid.2008.05.421
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Background: Infection control programs in dental clinics
are essential to prevent of infectious transmission among
personnel and patients. The program usually starts by eval-
uation of risk factors and completed by designing a suitable
strategy for removal of them. The present study assessed
the infection control situation of private dental ofﬁces in
Bandar Abbas, southern Iran, during year 2006.
Materials & Methods: sixty dental were investigated
using a cross- sectional study in a 6 months period. A stan-
dard questionnaire was used to collect data (correspondence
rate was 82%). The questionnaire contained 46 questions
about demographic information, knowledge and practice of
dentists about infection control and hygienic condition of
clinics. Data was analyzed using T and Pearson tests.
Results: vaccination rate against hepatitis B was 43.5
percent, among selected dentists, 75% of them were not
conﬁdent about antibody production in their body. Eighty
and 15% of questioned dentists used personal protec-
tion equipments and mouth washing solution respectively.
Correct answer to questions on instruments sterilization,
properly hand washing procedures and subcutaneous infec-
tion control were 74, 56.7 and 34 percent respectively.
Special containers were used for infectious disposal in 82
percent, of which, 60 percent were labeled. Seventy four
percent of dentists were conﬁdent about accurate steriliza-
tion of instruments, but 50% of them were not conﬁdent
that instruments remained sterilized till operation. Average
score of knowledge, practice, and hygienic clinics situa-
tion in female and male dentist were (10.1 ± is & # 1.73,
11.1± is & # 1.79), (14.4± is± 1.40, 13.6± is± 1.73) and
(16.6± is ± 1.13, 16± is± 1.26) respectively.
Conclusion: In our quality assessments, the knowledge
and practice level of selected dentists were intermedi-
ate and environmental health situation of clinics was ﬁnd
high scored. According to relationship between knowledge
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and practice, infection control rate will be promoted using
related educational programs.
doi:10.1016/j.ijid.2008.05.422
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Background: The pathogen strain of Bacillus anthracis
A0843, isolated during an anthrax outbreak occurred in Italy,
belongs to the Cluster A1a genotype 3. The authors show its
activity underlining that the regular behaviour could make
it useful as a reference strain for subcutaneous challenge in
rabbit model for anthrax vaccines efﬁcacy test. Italy doesn’t
use Ames strain because the restrictive measures, imposed
after the bioterroristic events occurred in October 2001 in
USA, reduced the movements of pathogen agents between
reference laboratories in the world. It is necessary to adopt
new rules that favour the security and the regularity of the
research.
Method: This study was done, during 3 years, on 50 New
Zeeland rabbits, males and females, with a weigh between
1.200 and 1500 grams. The site of injection was back in
the space between the two scapulae. It was used 20 LD50
(about 40.000 spores) of the pathogen strain according to
the European Pharmacopoeia.
Results: It was observed that anthrax begins to kills after
48 hours from the infection. At 72 hours the percentage of
survival is 56,66%; at 96 hours is 30%. It was observed that
two animals that survived after 120 hours from infection
didn’t die.
Conclusion: The LD50 of B. anthracis strain A0843 in rab-
bit is 2.000 spores, less virulent then Ames strain which is
characterized of a LD50 of about 1.200 spores. The standard
amount of 20 DL50 (about 40.000 spores) of B. anthracis
strain A0843 injected in subcutaneous area in rabbits shows
a linear behaviour. The higher mortality is observed between
72 and 96 hours. All the animals died within 120 hours from
the infection. None of the infected animals survived over
this time and we consider it the survival line of anthrax
subcutaneous challenge in rabbit.
Technical support: Angela Aceti and Nicola Nigro
Founds: Ricerca Corrente 2005 of Ministry of Health of
Italy
This research was done in according to the Decreto leg-
islativo n.116/92 on animal welfare
doi:10.1016/j.ijid.2008.05.423
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Background: Aﬂatoxins are well-known secondary
metabolites of the mould Aspergillus ﬂavus, but it is not
clear whether aﬂatoxins are produced in tissues in the
course of invasive aspergillosis due to aﬂatoxinogenic
Aspergillus ﬂavus strains. We sought to determine whether
aﬂatoxin B1 is produced in tissues in experimental invasive
aspergillosis due to aﬂatoxinogenic Aspergillus ﬂavus.
Methods: Corticosteroid-treated (immunosuppressed)
Wistar rats received intravenous challenge with conidia from
a known aﬂatoxin B1-producing strain of Aspergillus ﬂavus
(test rats) or with conidia from a aﬂatoxin non-producing
strain of Aspergillus ﬂavus (control rats). Animals were sac-
riﬁced after 10 days and key organs dissected out. Thin-layer
chromatography was used to detect aﬂatoxin B1 in tissue
homogenates; in addition, total protein concentration and
protein proﬁles were determined. Histopathological studies
were also done.
Results: Aﬂatoxin B1 was detected in concentrations of
120 ppb and 70 ppb, respectively, in homogenates of liver
and kidney of test rats, but was not detected in tissue
homogenates from control rats. The total protein concen-
tration as well as the protein proﬁles of homogenates of the
liver, kidneys, eyes and spleen of test rats tended to show
much greater alterations than those in control rats. Invasion
of tissue by fungal hyphae tended to be more intense in test
than in control rats, while the histoarchitecture of liver, kid-
ney and spleen tissues underwent greater disruption in test
than in control rats.
Conclusions: Aﬂatoxin B1 is produced in tissues in
experimental invasive aspergillosis due to aﬂatoxinogenic
Aspergillus ﬂavus and may account for the pronounced
alterations in protein proﬁles and histoarchitecture com-
pared to that occurring in invasive aspergillosis due to
aﬂatoxin non-producing Aspergillus ﬂavus.
doi:10.1016/j.ijid.2008.05.424
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Background: T-705, an oral anti-inﬂuenza virus agent dis-
covered by Toyama Chemical. Co., Ltd., and is currently
under clinical development. T-705 exhibits in vitro and in
vivo antiviral effect against inﬂuenza A and B. Further-
